Be a part of a new era
in cellular therapy

for the potential treatment of human papillomavirus (HPV) 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer).

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite this progress, existing immunotherapies are effective in a relatively small number of patients with HPV 16-associated cancers. Furthermore, in some cases even when therapies are initially effective, the disease eventually no longer responds to treatment and progresses.

Rubius Therapeutics® is developing an investigational cellular therapy, called RTX-321, that is engineered to selectively target HPV 16-associated cancers and potentially induce an immune response against the cancer, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer).

About RTX-321
RTX-321 is an investigational cellular therapy that aims to selectively target HPV 16-associated cancers and potentially induce an immune response against the cancer.

RTX-321 is an investigational cellular therapy that is being evaluated in a Phase 1 clinical trial for the treatment of patients with HPV 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer). RTX-321 is engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the cell surface may selectively instruct only the cells of the immune system with the ability to potentially recognize and attack the tumor.

Learn more about the RTX-321 Clinical Trial